The p.S37C mutation accounts for only 2.8% of all 6939 CTNNB1 mutations analyzed in various mesenchymal and epithelial neoplasms, including hepatocellular, endometrial, ovarian, and pituitary tumors, according to COSMIC (April 2018). This evidence concerns the gene CTNNB1 and epithelial neoplasm.